Vaxcyte Quarterly Income Statement
NASDAQ: PCVXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
71.38+6.37 (+9.79%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vaxcyte revenue and earnings
Vaxcyte reported a net loss of $284.3 million, compared with a loss of $166.6 million a year earlier. Diluted earnings per share came in at -$1.97.
Summary generated from market data by MetaCap's automated system. Methodology
Vaxcyte income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 302.78M | 345.85M | 274.28M | 242.38M | 226.22M | 180.79M | 162.17M | 139.92M | 152.98M | 114.47M | 196.68M | 113.03M |
| Research & Development | 267.85M | 312.78M | 242.06M | 209.93M | 194.18M | 148.13M | 133.61M | 116.94M | 131.51M | 94.59M | 104.15M | 97.42M |
| Operating Income | -302.78M | -345.85M | -274.28M | -242.38M | -226.22M | -180.79M | -162.17M | -139.92M | -152.98M | -114.47M | -196.68M | -113.03M |
| Interest Expense | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Other Income (Expense) | 18.48M | 25.23M | 27.78M | 29.55M | 59.65M | 40.08M | 25.09M | 36.80M | 24.28M | 19.45M | -47.03M | 20.36M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -284.30M | -320.62M | -246.51M | -212.83M | -166.57M | -140.72M | -137.08M | -103.12M | -128.70M | -95.02M | -180.80M | -92.66M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.97 | -2.30 | -1.81 | -1.56 | -1.22 | -1.04 | -1.02 | -0.83 | -1.10 | -0.85 | -1.83 | -0.91 |
| EPS (Diluted) | -1.97 | -2.30 | -1.81 | -1.56 | -1.22 | -1.04 | -1.02 | -0.83 | -1.10 | -0.85 | -1.83 | -0.91 |
| Shares Outstanding (Basic) | 144.49M | 139.51M | — | 136.20M | 136.03M | 135.69M | — | 123.69M | 117.26M | 111.69M | — | 101.67M |
| Shares Outstanding (Diluted) | 144.49M | 139.51M | — | 136.20M | 136.03M | 135.69M | — | 123.69M | 117.26M | 111.69M | — | 101.67M |
| EBITDA | -299.77M | -342.90M | -266.79M | -239.32M | -223.34M | -177.84M | -159.31M | -138.14M | -151.63M | -113.47M | -195.79M | -112.22M |
This table shows 12 quarterly periods of Vaxcyte's income statement, from Q2 2026 back to Q3 2023, across 12 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow PCVX's reporting calendar. What is a income statement?